Posts Tagged ‘Larsen’

3D echo mitral valve reconstruction – validity of a novel software application

3D echocardiographic reconstruction of the mitral valve may optimise mitral surgery planning and potentially identifies patient-valve mismatch. The aim of this pilot study was to validate a novel 3D echo mitral reconstruction software allowing measurements of mitral structures by subsequent comparison to implanted prosthetic mitral valves or annuloplasty rings.

M. Wolbinski, A. Morgan, P. Larsen, A. Sasse
Wellington Regional Hospital, Wellington
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

“Normal” coronary arteries in the setting of acute coronary syndrome: Frequency and outcomes

A proportion of patients presenting with acute coronary syndrome (ACS) are found to have non-obstructive coronary disease on angiography. We investigated the frequency and impact of this finding in our ACS population.

S. Plunkett, A. Ranchord, P. Matsis, A. Holley, P. Larsen, S. Harding
Wellington Regional Hospital, Wellington
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Does timing of platelet function testing (PFT) contribute to variability in residual on-treatment platelet reactivity in patients with acute coronary syndrome (ACS)?

ACS patients on dual antiplatelet therapy display large variations in residual platelet reactivity. In part, this may reflect the dynamic nature of the ACS process. Understanding the impact of the timing of measurement on this variability is required. This study examined the effect of time from symptom onset to testing and from antiplatelet agent loading to testing on residual platelet reactivity.

C. Legge, A. Al-Sinan, A. Holley, L. Johnston, P. Larsen, S. Harding
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Variability and prognostic significance of antioxidant enzymes in acute coronary syndromes (ACS)

Glutathione peroxidase (GPx) and superoxide dismutase (SOD) are antioxidant enzymes which scavenge reactive oxygen species (ROS) and protect against oxidative stress. The variance and prognostic significance of these enzymes in ACS is unclear. This study examined the relationship between GPx and SOD activity and MACE following ACS.

A. Holley, J. Miller, S. Harding, P. Larsen
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Platelet count and platelet function testing in acute coronary syndromes

Platelet function testing may be a useful tool for tailoring antiplatelet therapy in acute coronary syndromes (ACS). Measurements of platelet function may be influenced by platelet count. We examined the relationship between platelet count and platelet function testing using two commercially available platelet function tests, VerifyNow and Multiplate.

K. Hally, L. Johnston, A. Holley, P. Larsen, S. Harding
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Spatial QRS-T angle following acute coronary syndromes

The ECG derived spatial QRS-T angle provides a measure of ventricular repolarisation abnormality, and enlarged QRS-T angle (greater than 100 degrees) has been correlated with increased mortality risk following acute coronary syndromes (ACS). In this study we examined the proportion of ACS patients with a greater than 100 degree QRS-T angle, and the effects of revascularisation following ACS on QRS-T angle.

S. Blomfield, B. Shi, S. Harding, P. Larsen
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

The effect of programming on therapy rates in implantable cardioverter defibrillator patients

While implantable cardioverter defibrillators (ICDs) have improved survival in those at high risk of sudden death, delivery of inappropriate therapy has been associated with negative impacts on quality of life and may increase mortality. Programming strategies to reduce both appropriate shocks for non-lethal ventricular tachycardia and inappropriate therapy for supraventricular tachycardia have been developed. In this study we compared therapy rates in ICD patients programmed using a standardised approach with those having individually customised programming.

S. Levings, M. Stiles, S. Heald, A. Jimenez, B. Shi, S. Harding, P. Larsen

Temporary and permanent discontinuation of clopidogrel following acute coronary syndromes

Premature discontinuation of clopidogrel following an Acute Coronary Syndrome (ACS) has been linked to an increased risk of adverse events. We examined the frequency and causes of clopidogrel discontinuation in the first year following ACS.

D. Middleditch, B. Scott, M. Simmonds, A. Aitken, L. Johnston, P. Larsen, S. Harding
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Acute coronary syndromes in patients with prior MI: Secondary prevention and outcomes

Long-term compliance with secondary prevention in patients with established cardiovascular disease is variable despite a high ongoing risk of cardiovascular events. We examined the prescription of secondary prevention medications and outcomes amongst patients with a prior myocardial infarction (MI) re-presenting with an acute coronary syndrome (ACS).

S. Fairley, S. Harding, M. Liang, A. Aitken, A. Ranchord, P. Larsen
Wellington Hospital, Cardiology Unit, Wellington
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

The effects of ticagrelor on platelet reactivity and short term outcomes in acute coronary syndromes

Ticagrelor, a more potent P2Y12 receptor antagonist, has recently been introduced into clinical practice. We examined the effect of ticagrelor on platelet reactivity, and short term outcomes in an ACS population.

A. Al-Sinan, P. Matsis, M. Simmonds, L. Johnston, P. Larsen, S. Harding
Wellington Hospital, Wellington
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Interested in joining CSANZ?